Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06967558 · ClinicalTrials.gov registry record · Phase 2

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

A Phase 2 study of PreDiabetes, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT06967558 is a Phase 2 study of PreDiabetes that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06967558, a Phase 2 study of PreDiabetes, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed. In this experiment we will use blockade of GLP1R to probe the contribution of endogenous GLP-1 secretion to the regulation of fasting glucose and islet function in prediabetes.

Conditions Studied

Interventions

  • BIOLOGICAL Saline
  • BIOLOGICAL Exendin 9-39

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-11-01
Est. Completion 2028-03-31
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06967558

The ClinicalTrials.gov registry entry for NCT06967558 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (91% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.

NCT06967558 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06967558 about?

NCT06967558 is a clinical study titled "The Role of Islet GLP-1 in the Pathogenesis of Prediabetes". We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP...

What is the current status of trial NCT06967558?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-11-01. Estimated completion is 2028-03-31.

What conditions does trial NCT06967558 study?

This clinical trial studies the following conditions: PreDiabetes.

What interventions are being tested in trial NCT06967558?

The interventions under investigation include: Saline (BIOLOGICAL), Exendin 9-39 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06967558?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06967558 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PreDiabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.